Last reviewed · How we verify
NCT05943080
Comparison of IPACK Block and PCI for Postoperative Analgesia and Function Recovery Following Total Knee Arthroplasty
NA trial testing PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline) in Total Knee ArthroplastyKnee Pain, Functionality in 195 participants. Completed in 15 December 2023.
10 August 2023
Quick facts
| Lead sponsor | Kirsehir Ahi Evran Universitesi |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 195 |
| Start date | 1 June 2023 |
| Primary completion | 10 August 2023 |
| Estimated completion | 15 December 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline) — full drug profile →
- IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline) — full drug profile →
- ACB ( 0.25% marcaine + %0.9 saline) — full drug profile →
Conditions studied
- Total Knee ArthroplastyKnee Pain, Functionality — all drugs for Total Knee ArthroplastyKnee Pain, Functionality →
Sponsor
Kirsehir Ahi Evran Universitesi — full company profile →
Who can join
Adults 40 to 90, any sex, with Total Knee ArthroplastyKnee Pain, Functionality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It was planned to determine the most effective single and/or combined use in daily use by evaluating the effect on pain control and functional status by combining the posterior capsuler infiltration (PCI) and interspace between the popliteal artery and the capsule of the posterior knee(IPACK block) performed during total knee replacement surgery with the adductor canal block method. In the randomized controlled study: Group 1; By determining the anatomical landmarks to be applied by the intraoperative surgeon, PCI + Adductor canal block (ACB) without any additional imaging, Group 2; IPACK+ACB applied by the anesthesiologist with the help of post-operative USG, In Group 3, there are 3 groups in which only ACB application is made. VAS values and opioid consumption of the groups will be recorded as the primary outcome after the surgery. As a secondary outcome, the 1st day rehabilitation initiation times and endurance of the patients With 1.2. and on Day 3 joint ranges of motion will be recorded.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
No superior method for analgesia after total knee arthroplasty: randomised controlled comparison of adductor canal block combined with iPACK block versus posterior capsule block.
Cakmak MF, Bayram S, Horoz L, Arslan FN, et al · · 2025 · cited 1× · PMID 40186749 · DOI 10.1007/s00402-025-05845-5
Verify or expand the search:
- PubMed search for NCT05943080
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kirsehir Ahi Evran Universitesi trials
Trials by the same sponsor.
- NCT07506915 — The Effect of Cognitive Behavioral Therapy · NA · enrolling by invitation
- NCT07502248 — PENG Block With or Without PPD Block for Postoperative Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
- NCT07438392 — Tecar Therapy in Chronic Knee Osteoarthritis · NA · not yet recruiting
- NCT07450742 — Digital Storytelling and Mother's Knowledge and Attitudes Towards Newborn Screning · NA · not yet recruiting
- NCT07414017 — Comparison of Focus of Attention in Virtual Reality-Based Exercise Training in Older Adults With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05943080 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kirsehir Ahi Evran Universitesi
- Last refreshed: 7 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05943080.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing